Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatl...

Full description

Bibliographic Details
Main Authors: Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato, Carlo Genova
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
NSCLC
biomarker
immune checkpoint inhibitor
tumor mutational burden
PD-L1
T-Cell clonality
Online Access:https://www.mdpi.com/2072-6694/12/5/1125

Internet

https://www.mdpi.com/2072-6694/12/5/1125

Similar Items